Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Quick Read XOM and JNJ earn 'Very Safe' dividend ratings inside HDV, backed by interest coverage of 56x and 64 consecutive annual raises. AbbVie's Skyrizi and Rinvoq are replacing Humira faster than expected, but Net Debt/EBITDA of 2.3x keeps a watchlist tag on its …
Sharemaestro market context Trend signal active 52 weeks +50.4%Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid …
In Q2 2026, the biopharma industry experienced a significant sales boom, with nine of the top 25 drugmakers achieving double-digit year-over-year revenue increases, and 13 showing double-digit sequential gains. Companies like Eli Lilly, Sanofi, Regeneron, and Astellas were prominent leaders in this growth. Many …
Novo Nordisk CEO Mike Doustdar believes there is a significant future for weight-loss drugs like Wegovy, as only a small percentage of eligible Americans currently use GLP-1 medications despite over 100 million suffering from obesity. Doustdar highlighted that wider adoption of these drugs could …
Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about …
European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …
Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …
Sharemaestro market context Price above Trend Line 52 weeks -5.7%Pfizer is shifting its growth strategy away from COVID-19 products, focusing instead on its non-COVID portfolio through new product launches, strategic acquisitions, and pipeline development in oncology and obesity. The company's recent Q2 2026 results showed significant operational growth in non-COVID revenues, leading to …
Sharemaestro market context Price above Trend Line 52 weeks +12.0%Eli Lilly has filed six new lawsuits to combat the black-market sale of its experimental obesity medicine, retatrutide. The drugmaker is taking action against online merchants, clinics, compounders, and foreign companies that claim to offer versions of its highly anticipated weight loss drug before …
Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. …
Sharemaestro market context Price below Trend Line 52 weeks +15.5%Eli Lilly has filed lawsuits against six companies in the United States for allegedly selling illegal, unapproved versions of its experimental weight-loss drug, retatrutide. These companies include compounding pharmacies, medical spas, and online sellers falsely claiming the knockoffs are for "research-use only." This action …
Key Points The "Magnificent Seven" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we …
Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading
Formation Bio has appointed Dr. Michael Ehlers, a former Biogen and Pfizer executive, as its new chief scientific officer and head of R&D. The company aims to leverage AI to optimize the often-overlooked "boring middle" of drug development, such as trial enrollment and site …
Sharemaestro market context Price above Trend Line 52 weeks +12.0%Amgen's stock is trading near a yearly high after reporting strong Q2 2026 results, with EPS of $6.29 beating estimates by $0.67 and revenue reaching $10.05 billion. The company also raised its full-year EPS guidance and announced a quarterly dividend, alongside positive news regarding …
[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the …
Sharemaestro market context Trend signal active 52 weeks +57.8%Daiwa Securities Group upgraded Merck & Co., Inc. (NYSE:MRK) from "neutral" to "outperform" with a $143 price target. This upgrade comes as Merck reported strong quarterly revenue of $16.61 billion, exceeding estimates, and adjusted EPS of $(0.13), also beating consensus. Despite favorable analyst sentiment …
Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of "Crowding Out Competitors" is strategically smart. Analyst Suraj Kalia said the change reflects "a more nuanced risk-reward assessment at …
Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its …
Sharemaestro market context Trend signal active 52 weeks +50.4%This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson …
Quick Read The S&P 500's combined dividend yield hit a record-low 1.04%, but five index members still deliver dividends of 6% or more, all rated Buy. General Mills (GIS) yields 6.9% at just 10x 2026 earnings, while Verizon (VZ) has raised its dividend for …
AstraZeneca PLC (AZN) shares fell 1.20% to £117.02 on Wednesday, underperforming the broader market as the FTSE 100 Index (UKX) also dropped. The company's stock closed 25.62% below its 52-week high.
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. …
Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released …
Sharemaestro market context Trend signal active 52 weeks +57.8%Sanofi is reorganizing its Executive Committee, effective September 1, 2026, to expand the finance function's responsibilities and consolidate its senior leadership. The finance division will now oversee enterprise business services, Global Partnering, Business Development, and M&A, with François Roger remaining as EVP of Finance. …
Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular …
Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus …
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation …
Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%Insight Wealth Strategies LLC significantly increased its stake in Biogen Inc. by 16.9% in the second quarter, now holding 34,320 shares valued at $7.20 million. This comes as Biogen reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, with revenue growing …
Wedge Capital Management L L P NC increased its stake in AbbVie Inc. (NYSE:ABBV) by 7.5% in the second quarter, bringing its total holdings to 134,579 shares valued at $33.9 million. This comes as AbbVie reported strong quarterly results, beating EPS and revenue estimates, …
Tema ETFs LLC significantly increased its stake in Amgen Inc. by 14.5% during the second quarter, bringing its total holdings to 26,231 shares valued at approximately $9.5 million. This move comes as Amgen reported strong Q2 earnings, beating analyst estimates with EPS of $6.29 …
Erste Group Bank has lowered its FY2026 EPS forecast for Gilead Sciences to a loss of $0.75 per share, below the consensus estimate of a $0.50-per-share loss. Despite this, analyst sentiment remains a "Moderate Buy" with an average price target of $158.04. Gilead reported …
Search by ticker symbol or company name and select a result to open its chart.